Complications associated with the use of bone morphogenetic protein in pediatric patients

Journal of Pediatric Orthopaedics

Volumn 30, Issue 2, 2010, Pages 192-198

  Oetgen, Matthew E ^a   Richards, B Stephens ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

Author keywords

Bone morphogenetic protein; Complications; Pediatrics

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ADOLESCENT; ADULT; BONE RADIOGRAPHY; CARCINOGENICITY; CHILD; COMPARTMENT SYNDROME; FEMALE; GLIOMA; HUMAN; INFECTION; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROFIBROMATOSIS; NEUROLOGICAL COMPLICATION; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SPINAL CORD DISEASE; WEAKNESS;

ADOLESCENT; BONE MORPHOGENETIC PROTEINS; CHILD; CHILD, PRESCHOOL; DURA MATER; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; FRACTURE HEALING; FRACTURES, UNUNITED; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77649131474     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/BPO.0b013e3181d075ab     Document Type: Review

References (23)

1. Termaat MF, Den Boer FC, Bakker FC, et al. Bone morpho-genetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am. 2005;87: 1367-1378.
2. Urist MR. The substratum for bone morphogenesis. Symp Soc Dev Biol. 1970;29:125-163.
3. Anticevic D, Jelic M, Vukicevic S. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morpho-genetic protein-7): a case report. J Pediatr Orthop B. 2006;15: 220-221.
4. Fabeck L, Ghafil D, Gerroudj M, et al. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Br. 2006;88:116-118.
5. Kujala S, Vahasarja V, Serlo W, et al. Treatment of congenital pseudarthrosis of the tibia with native bovine BMP: a case report. Acta Orthop Belg. 2008;74:132-136.
6. Oluigbo CO, Solanki GA. Use of recombinant human bone morphogenetic protein-2 to enhance posterior cervical spine fusion at 2 years of age: technical note. Pediatr Neurosurg. 2008;44: 393-396.
7. Lee FY, Sinicropi SM, Lee FS, et al. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morpho-genetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am. 2006;88:627-633.
8. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27: 2662-2673.
9. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-349.
10. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002;27: 2396-2408.
11. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83-A(suppl 1):S151-S158.
12. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br. 1999;81:710-718.
13. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84-A:2123-2134.
14. Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereo-metric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine. 2002;27:2654-2661.
15. Jones AL, Bucholz RW, Bosse MJ, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am. 2006;88: 1431-1441.
16. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 2002;27:S40-S48.
17. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 y) pivotal study. Spine. 2008;33:2850-2862.
18. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006;31: 542-547.
19. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine. 2007;32:2885-2890.
20. Paramore CG, Lauryssen C, Rauzzino MJ, et al. The safety of OP-1 for lumbar fusion with decompression - a canine study. Neurosurgery. 1999;44:1151-1155.
21. Carreon LY, Glassman SD, Brock DC, et al. Adverse events in patients re-exposed to bone morphogenetic protein for spine surgery. Spine. 2008;33:391-393.
22. Krause F, Younger A, Weber M. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. J Bone Joint Surg Am. 2008;90:1168.
23. Dobbs MB, Rich MM, Gordon JE, et al. Use of an intramedullary rod for the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Am. 2005;87:33-40.